VEPESID

This brand name is authorized in Australia, Austria, Canada, Estonia, Finland, Ireland, Japan, Malta, Netherlands, New Zealand, Romania, Spain, UK.

Active ingredients

The drug VEPESID contains one active pharmaceutical ingredient (API):

1	Etoposide UNII 6PLQ3CP4P3 - ETOPOSIDE
	The main effect of etoposide appears to be at the late S and early G2 portion of the cell cycle in mammalian cells. The predominant macromolecular effect of etoposide seems to be the rupture of the double strand by an interaction with DNA-topoisomerase II or by the formation of free radicals. Etoposide has been shown to cause metaphase arrest in chick fibroblasts.
	Read more about Etoposide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VEPESID Capsule, soft	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01CB01	Etoposide	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CB Podophyllotoxin derivatives
Discover more medicines within L01CB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1389D, 1396L
CA	Health Products and Food Branch	00616192
EE	Ravimiamet	1036202, 1036213, 1069691, 1674367, 1853344
ES	Centro de información online de medicamentos de la AEMPS	56108, 56488
FI	Lääkealan turvallisuus- ja kehittämiskeskus	073783
GB	Medicines & Healthcare Products Regulatory Agency	44304, 44307
IE	Health Products Regulatory Authority	88205, 88206
JP	医薬品医療機器総合機構	4240001M1075, 4240001M2071, 4240403A2050
MT	Medicines Authority	AA565/18502, AA565/18503
NL	Z-Index G-Standaard, PRK	16004, 22276
NZ	Medicines and Medical Devices Safety Authority	3480, 3483
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66186001, W66186002, W66187001, W66187002